Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Kuke Brings AI-Powered Piano Lessons to 4,000 Kindergartens
SmartMore Bags $200 Million in Fresh Funding as China Pushes for AI in Manufacturing
TikTok Rival Kuaishou Wins Rights to Tokyo and Beijing Olympics
Geely’s New SUV to Include Smart Cockpit System Developed Partly by Ecarx
Tesla Opens Solar-Powered Charging Station in Tibet's ‘City of Sunlight’
Nissan-Backed Chinese Self-Driving Startup WeRide Raises $310 Million
Amazon Buys Automated Driving Systems From Plus, Considers Stake Purchase
Online Grocers Dingdong Maicai and Missfresh Set Terms for U.S. IPOs
Baidu Joins Caravan of Chinese Tech Giants Targeting Carbon Neutrality
Chinese Brands Rising in Global Esteem, Analytics Firm Says
Trending in China: Wave of Disbelief Greets Proposal of Award for Academic’s Work Debunking Einstein
Alibaba Cloud Remains Top Dog in China by Wide Margin
Geely-Owned Volvo to Develop Electric-Vehicle Batteries With Northvolt
Online Tutoring Startup Spark Education Files for U.S. IPO as Regulators Crack Down at Home
Chinese Smartphone Brands Play Catch-Up With Apple in Global 5G Race
Zvision’s Latest Funding Round Shows Investor Interest in Lidar Has Got Range
Trending in China: Venerated Literary Translator Xu Yuanchong Dies at Age 100
Apple Touch-Screen Supplier Biel Crystal Plans Second Bite at Hong Kong Listing
Stop Annoying China With Spam Texts, E-Commerce Giants Told
Baidu Partners With Automaker BAIC on New Apollo Robotaxi
German Drugmaker BI Launches Shanghai Center to Harness Chinese Expertise

By Ding Yi / Jul 03, 2020 04:35 PM / Business & Tech

Photo: Visual China

Photo: Visual China

German pharmaceutical firm Boehringer Ingelheim (BI) has launched its External Innovation Hub in Shanghai in a bid to harness China’s expertise in life science innovation to power its global drug discovery and development chain.

A big feature of the hub is that the facility adopts a so-called “3-in-1” system, meaning that it will integrate BI’s external-facing functions including Research Beyond Borders (RBB), Business Development & Licensing (BD&L) and BI Venture Fund (BIVF) under one roof, according to a statement by the company Thursday.

RBB is a global research unit BI likens to a “radar” that can detect the next big wave of innovation in life science. The BD&L team and the BIVF together play a role in turning scientific approaches into business ideas.

The hub will also create various partnerships to help BI sharpen its core therapeutic capabilities, meet urgent medical needs and possibly identify therapeutic areas for future strategic investment.

The launch of the Shanghai hub comes three months after BI unveiled a plan to open a digital lab in July in the same city, with plans to recruit dozens of experts in digital healthcare to help develop medicines and therapies for the Chinese market.

In a separate post published on its public WeChat account, BI said that it plans to invest 451 million euros ($508 million) over the next five years in China, a market it entered more than two decades ago.

Since its entry into China, BI has forged partnerships with multiple local academic institutions and companies in the country including Tsinghua University and Peking University, the company said.

In recent years, foreign drugmakers have increased investment in China, where the government aims to grow the healthcare industry to 8 trillion yuan ($1.1 trillion) by the end of 2020 and 16 trillion yuan by 2030

Contact reporter Ding Yi (yiding@caixin.com)

Related: German Drugmaker BI to Establish Digital Lab in Shanghai


Share this article
Open WeChat and scan the QR code